NGF blockade at early times during bone cancer development attenuates bone destruction and increases limb use.
暂无分享,去创建一个
P. Mantyh | M. Thompson | Lisa A. Majuta | G. McCaffrey | Geraldine Longo | Michelle N. Fealk | Stephane R. Chartier | G. Mccaffrey
[1] E. Bruera,et al. Factors associated with survival after opioid rotation in cancer patients presenting to an outpatient supportive care center. , 2014, Journal of pain and symptom management.
[2] S. Mellis,et al. Fasinumab (REGN475), an antibody against nerve growth factor for the treatment of pain: Results from a double-blind, placebo-controlled exploratory study in osteoarthritis of the knee , 2014, PAIN®.
[3] P. Mantyh. The neurobiology of skeletal pain , 2014, The European journal of neuroscience.
[4] A. Russo,et al. Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor , 2014, Expert opinion on biological therapy.
[5] P. Mantyh. Bone cancer pain: Causes, consequences, and therapeutic opportunities , 2013, PAIN®.
[6] N. Lane,et al. Nerve growth factor: an update on the science and therapy. , 2013, Osteoarthritis and cartilage.
[7] C. Farrell. Bone metastases: assessment, management and treatment options. , 2013, British journal of nursing.
[8] C. Bokemeyer,et al. Reducing the burden of bone metastases , 2013, Supportive Care in Cancer.
[9] P. Mantyh,et al. Disease modification of breast cancer–induced bone remodeling by cannabinoid 2 receptor agonists , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[10] H. Hondermarck,et al. Neurotrophins and their receptors in breast cancer. , 2012, Cytokine & growth factor reviews.
[11] P. Mantyh,et al. Neuroplasticity of sensory and sympathetic nerve fibers in a mouse model of a painful arthritic joint. , 2012, Arthritis and rheumatism.
[12] J. Grauer,et al. Current Advances in Training Orthopaedic Patients to Comply with Partial Weight-Bearing Instructions , 2012, The Yale journal of biology and medicine.
[13] B. Schmidt,et al. Nerve Growth Factor Links Oral Cancer Progression, Pain, and Cachexia , 2011, Molecular Cancer Therapeutics.
[14] P. Mantyh,et al. Breast cancer-induced bone remodeling, skeletal pain, and sprouting of sensory nerve fibers. , 2011, The journal of pain : official journal of the American Pain Society.
[15] Paula Ravasco,et al. Definition and classification of cancer cachexia: an international consensus. , 2011, The Lancet. Oncology.
[16] S. Mercadante. Managing Breakthrough Pain , 2011, Current pain and headache reports.
[17] A. Gorman,et al. Nerve Growth Factor in Cancer Cell Death and Survival , 2011, Cancers.
[18] P. Mantyh,et al. Blockade of nerve sprouting and neuroma formation markedly attenuates the development of late stage cancer pain , 2010, Neuroscience.
[19] P. Mantyh,et al. A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss. , 2010, Life sciences.
[20] S. Ohtori,et al. Role of low-affinity nerve growth factor receptor inhibitory antibody in reducing pain behavior and calcitonin gene-related Peptide expression in a rat model of wrist joint inflammatory pain. , 2010, The Journal of hand surgery.
[21] P. Mantyh,et al. Administration of a tropomyosin receptor kinase inhibitor attenuates sarcoma-induced nerve sprouting, neuroma formation and bone cancer pain , 2010, Molecular pain.
[22] H. Hondermarck,et al. Nerve growth factor is a potential therapeutic target in breast cancer. , 2008, Cancer research.
[23] Ryan J. Buus,et al. Nerve growth factor sequestering therapy attenuates non-malignant skeletal pain following fracture , 2007, PAIN®.
[24] Ryan J. Buus,et al. Effects of a Monoclonal Antibody Raised Against Nerve Growth Factor on Skeletal Pain and Bone Healing After Fracture of the C57BL/6J Mouse Femur , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[25] K. Baldwin,et al. What's New in Orthopaedic Rehabilitation. , 2007, The Journal of bone and joint surgery. American volume.
[26] Joachim Weis,et al. The Dark Side of the NGF Family: Neurotrophins in Neoplasias , 2006, Brain pathology.
[27] P. Mantyh,et al. Analgesic efficacy of bradykinin B1 antagonists in a murine bone cancer pain model. , 2005, The journal of pain : official journal of the American Pain Society.
[28] P. Mantyh,et al. A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. , 2005, Cancer research.
[29] J. Pons,et al. Nerve growth factor mediates hyperalgesia and cachexia in auto-immune arthritis , 2005, Pain.
[30] P. Mantyh,et al. Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization , 2005, Pain.
[31] P. Mantyh,et al. Different tumors in bone each give rise to a distinct pattern of skeletal destruction, bone cancer‐related pain behaviors and neurochemical changes in the central nervous system , 2003, International journal of cancer.
[32] P. Mantyh,et al. Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2. , 2002, Cancer research.
[33] P. Mantyh,et al. Osteoprotegerin diminishes advanced bone cancer pain. , 2001, Cancer research.
[34] P. Mantyh,et al. Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons , 2000, Neuroscience.
[35] R. Urfer,et al. Antibody binding regions on human nerve growth factor identified by homolog- and alanine-scanning mutagenesis. , 2000, Hybridoma.
[36] P. Mantyh,et al. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord , 2000, Nature Medicine.
[37] P. Mantyh,et al. Neurochemical and Cellular Reorganization of the Spinal Cord in a Murine Model of Bone Cancer Pain , 1999, The Journal of Neuroscience.
[38] F. Coutts,et al. Gait analysis in the therapeutic environment. , 1999, Manual therapy.
[39] D. Clohisy,et al. Localized, tumor‐associated osteolysis involves the recruitment and activation of osteoclasts , 1996, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[40] D. Clohisy,et al. Tumor osteolysis in osteopetrotic mice , 1995, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.
[41] M. Zimmermann,et al. Ethical guidelines for investigations of experimental pain in conscious animals , 1983, Pain.
[42] Ramsin M. Benyamin,et al. Anti-nerve growth factor in the treatment of low back pain and radiculopathy: a systematic review and a meta-analysis. , 2014, Pain physician.
[43] K. Mystakidou,et al. The key role of bisphosphonates in the supportive care of cancer patients. , 2014, Anticancer research.
[44] D. Amadori,et al. Metastatic bone disease in the era of bone-targeted therapy: clinical impact. , 2013, Tumori.
[45] S. Abram. Preventive or late administration of anti-NGF therapy attenuates tumor-induced nerve sprouting, neuroma formation, and cancer pain , 2012 .
[46] A. Jemal,et al. Global Cancer Statistics , 2011 .
[47] J. Coyne,et al. A novel approach to the use of animals in studies of pain: validation of the canine brief pain inventory in canine bone cancer. , 2009, Pain medicine.
[48] E. Feuer,et al. SEER Cancer Statistics Review, 1975-2003 , 2006 .
[49] N. Hebela,et al. What's new in orthopaedic rehabilitation. , 2004, The Journal of bone and joint surgery. American volume.
[50] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[51] J. Perez-polo,et al. Nerve growth factor and neural oncology , 1983, Journal of neuroscience research.